By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Boehringer Ingelheim Release: Uninterrupted Pradaxa (Dabigatran Etexilate Mesylate) Showed Less Major Bleeding Than Warfarin In Atrial Fibrillation Patients Undergoing Catheter Ablation 3/20/2017 7:53:25 AM
Boehringer Ingelheim Release: Uninterrupted Pradaxa Showed Less Major Bleeding Than Warfarin In Atrial Fibrillation Patients Undergoing Catheter Ablation 3/20/2017 6:32:24 AM
Boehringer Ingelheim Phase III Study Now Enrolling Patients With Progressive Fibrosing Lung Diseases 3/20/2017 6:16:43 AM
FORMA Announces Achievement Of First Clinical Development Milestone In Partnership With Boehringer Ingelheim 3/13/2017 6:36:09 AM
Boehringer Ingelheim Grants Orphan Drug Designation To Boehringer Ingelheim's Investigational Anti-CD33 Monoclonal Antibody BI 836858 For Treatment Of Myelodysplastic Syndromes 3/9/2017 9:12:42 AM
Boehringer Ingelheim Expands Collaboration With Vanderbilt University To Tackle Some Of The Most Difficult-To-Treat Cancers 3/2/2017 6:21:08 AM
Boehringer Ingelheim Release: New Global Survey Results Show: 2 Out Of 3 Patients Said They Were Involved In The Decision-Making Process About The Most Appropriate Treatment In IPF 2/28/2017 6:51:59 AM
Real-World Data From Boehringer Ingelheim Show Lower Risk Of Stroke And Major Bleeding For Pradaxa (Dabigatran Etexilate Mesylate) Compared To Warfarin 2/24/2017 6:44:23 AM
Boehringer Ingelheim Release: FDA Expands Approval Of Tiotropium Respimat For Maintenance Treatment Of Asthma In Children 2/16/2017 9:22:51 AM
Boehringer Ingelheim Release: FDA Expands Approval Of SPIRIVA RESPIMAT (Tiotropium Bromide) Inhalation Spray For Maintenance Treatment Of Asthma In Children 2/16/2017 6:36:21 AM
12345678910...
//-->